Cargando…
Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro
The Tougu Xiaotong capsule (TXC) is a traditional herbal compound used to treat osteoarthritis (OA) in China. We performed fingerprint analysis with HPLC for the quality control of TXC. Its composition was identified by the comparison of the spectrogram and chromatographic peak of retention time wit...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939087/ https://www.ncbi.nlm.nih.gov/pubmed/31909121 http://dx.doi.org/10.1016/j.dib.2019.105023 |
_version_ | 1783484167162429440 |
---|---|
author | Li, Xihai Zhang, Zhenli Liang, Wenna Zeng, Jianwei Shao, Xiang Xu, Limei Jia, Liangliang He, Xiaojuan Li, Hui Zheng, Chunsong Ye, Hongzhi Asakawa, Tetsuya |
author_facet | Li, Xihai Zhang, Zhenli Liang, Wenna Zeng, Jianwei Shao, Xiang Xu, Limei Jia, Liangliang He, Xiaojuan Li, Hui Zheng, Chunsong Ye, Hongzhi Asakawa, Tetsuya |
author_sort | Li, Xihai |
collection | PubMed |
description | The Tougu Xiaotong capsule (TXC) is a traditional herbal compound used to treat osteoarthritis (OA) in China. We performed fingerprint analysis with HPLC for the quality control of TXC. Its composition was identified by the comparison of the spectrogram and chromatographic peak of retention time with a reference substance. TXC was found to contain paeoniflorin, isofraxidin, ferulic acid, and rosmarinic acid. The chondrocytes were identified by immunohistochemical staining using collagen II. Chondrocytes that were positive for collagen II were stained brown in the cytoplasm. The toll-like receptor 4 (TLR4) was expressed on the chondrocyte membrane, which was observed using immunofluorescence microscopy. The nuclei were stained blue by 4′,6-diamidino-2-phenylindole (DAPI) and TLR4 was stained green. These were observed using laser scanning confocal microscopy. The successful establishment of LPS-exposed chondrocytes was confirmed using enzyme-linked immunosorbent assay (ELISA). Lipopolysaccharide (LPS) administration significantly reduced the levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), and a maximum effect was observed at 8 h. We believe that these methods will be useful in future investigations of OA. This data article is related to the research article “Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation: In vivo and in vitro verification” [1]. |
format | Online Article Text |
id | pubmed-6939087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-69390872020-01-06 Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro Li, Xihai Zhang, Zhenli Liang, Wenna Zeng, Jianwei Shao, Xiang Xu, Limei Jia, Liangliang He, Xiaojuan Li, Hui Zheng, Chunsong Ye, Hongzhi Asakawa, Tetsuya Data Brief Medicine and Dentistry The Tougu Xiaotong capsule (TXC) is a traditional herbal compound used to treat osteoarthritis (OA) in China. We performed fingerprint analysis with HPLC for the quality control of TXC. Its composition was identified by the comparison of the spectrogram and chromatographic peak of retention time with a reference substance. TXC was found to contain paeoniflorin, isofraxidin, ferulic acid, and rosmarinic acid. The chondrocytes were identified by immunohistochemical staining using collagen II. Chondrocytes that were positive for collagen II were stained brown in the cytoplasm. The toll-like receptor 4 (TLR4) was expressed on the chondrocyte membrane, which was observed using immunofluorescence microscopy. The nuclei were stained blue by 4′,6-diamidino-2-phenylindole (DAPI) and TLR4 was stained green. These were observed using laser scanning confocal microscopy. The successful establishment of LPS-exposed chondrocytes was confirmed using enzyme-linked immunosorbent assay (ELISA). Lipopolysaccharide (LPS) administration significantly reduced the levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), and a maximum effect was observed at 8 h. We believe that these methods will be useful in future investigations of OA. This data article is related to the research article “Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation: In vivo and in vitro verification” [1]. Elsevier 2019-12-19 /pmc/articles/PMC6939087/ /pubmed/31909121 http://dx.doi.org/10.1016/j.dib.2019.105023 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Medicine and Dentistry Li, Xihai Zhang, Zhenli Liang, Wenna Zeng, Jianwei Shao, Xiang Xu, Limei Jia, Liangliang He, Xiaojuan Li, Hui Zheng, Chunsong Ye, Hongzhi Asakawa, Tetsuya Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro |
title | Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro |
title_full | Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro |
title_fullStr | Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro |
title_full_unstemmed | Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro |
title_short | Data on Tougu Xiaotong capsules may inhibit p38 MAPK pathway-mediated inflammation in vitro |
title_sort | data on tougu xiaotong capsules may inhibit p38 mapk pathway-mediated inflammation in vitro |
topic | Medicine and Dentistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939087/ https://www.ncbi.nlm.nih.gov/pubmed/31909121 http://dx.doi.org/10.1016/j.dib.2019.105023 |
work_keys_str_mv | AT lixihai dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT zhangzhenli dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT liangwenna dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT zengjianwei dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT shaoxiang dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT xulimei dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT jialiangliang dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT hexiaojuan dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT lihui dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT zhengchunsong dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT yehongzhi dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro AT asakawatetsuya dataontouguxiaotongcapsulesmayinhibitp38mapkpathwaymediatedinflammationinvitro |